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Short Report
Antidepressant drugs and the response in the
placebo group: the real problem lies in our
understanding of the issue
Konstantinos N Fountoulakis1 and Hans-Ju¨rgen Mo¨ller2
Abstract
In a recent paper, Horder and colleagues (Horder et al., 2010, J Psychopharmacol 25: 1277–1288) have suggested that the main problem in the Kirsch
analysis is methodological. We argue that the results are similar irrespective of the method used. In our opinion the data suggest that placebo and drug
effects are non-additive: antidepressants act independently of depression severity, while the placebo effect is present only in milder cases. While the
response in the placebo group is due to unstable ‘noise’ and ‘artefacts’, the medication effect is reliable, valid and stable.
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Introduction
During the last decade, the usefulness of antidepressants in
clinical practice has been questioned, with meta-analytic stud-
ies suggesting their effect size is rather small (Bech et al., 2000;
Ghaemi, 2008; Moncrieff et al., 2004). Another issue is that
recently it has been documented that there is a significant bias
in the publication of antidepressant trials (Turner et al., 2008).
At the zenith of this discussion, the meta-analysis on the use-
fulness of antidepressants (Kirsch et al., 2008) attracted much
attention both from scientists and from the general public.
Kirsch and colleagues obtained data from the United States
Food and Drug Administration (FDA) and thus tried to avoid
publication bias. That meta-analysis reported that the effect
size and the magnitude of change in Hamilton rating scale for
depression (HRSD) score were small (effect size d-value below
0.50 and change in HRSD equal to 1.80 points) and thus
antidepressants fell well below criteria for clinical relevance
suggested by the National (UK) Institute for Clinical
Excellence (NICE). Similar findings were reported by Barbui
and colleagues for paroxetine alone (Barbui et al., 2008).
Kirsch et al. (2008) also reported that efficacy reaches clinical
relevance only in trials involving the most extremely depressed
patients, and that this pattern is due to a decrease in the
response to placebo rather than an increase in the response
to medication. They also found no linear relation between
severity and response to medication. More recently, Fournier
et al. (2010) have reported similar results, but on a much
different sample of randomized trials.
Kirsch went further and accused the FDA of having made
an explicit decision to keep this information from the public
and from prescribing physicians (Kirsch, 2009a). He also sug-
gested that because they do not incur drug risks, alternative
therapies (e.g. exercise and psychotherapy), showing equal
benefits to those of antidepressants, may be a better treatment
choice for depression (Kirsch, 2009a) and went on to author a
book under the title The Emperor’s New Drugs: Exploding the
Antidepressant Myth (Kirsch, 2009b). This was also the picture
painted in the media.
Several authors have criticized the above interpretation
(Bech, 2010; Broich, 2009; Ghaemi, 2008; McAllister-
Williams, 2008; Mo¨ller, 2008, 2009b, 2009c; Mo¨ller and
Broich, 2010; Mo¨ller and Maier, 2010b) by focusing on the
limitations of randomized controlled trials (RCTs) on clinical
issues, and especially on the problematic properties of the
HRSD (Bech, 2001, 2004, 2006, 2010; Bech et al., 2004) and
on the fact that the effectiveness of antidepressants in clinical
practice is normally optimized by sequential and combined
therapy approaches (Mo¨ller, 2009a; Rush, 2007).The useful-
ness of ‘alternative therapies’ was also discussed. Overall, psy-
chotherapy seems to be significantly less effective than
pharmacotherapy, since the effect size (in RCTs of lower qual-
ity than that of drugs) is close to the placebo effect size
(Cuijpers et al., 2010a, 2010b) and, in addition, it seems that
the publication bias is more pronounced concerning non-phar-
macological treatments (Cuijpers et al., 2010a). The results of
1Department of Psychiatry, School of Medicine, Aristotle University of
Thessaloniki, Thessaloniki, Greece
2Department of Psychiatry, Ludwig-Maximilians-University, Munich,
Germany
Corresponding author:
Konstantinos N Fountoulakis, 6 Odysseos str. (1st Parodos Ampelonon









 at LMU Muenchen on June 12, 2013jop.sagepub.comDownloaded from 
psychotherapy studies cannot be directly compared to results
of antidepressant trials; in spite of being based on RCT meth-
odology, in essence psychotherapy studies are not blinded, in
contrast to antidepressant trials (Mo¨ller and Maier, 2010a).
The data on the efficacy of exercise and other alternative ther-
apies, are either negative or do not exist.
Critical review of the issue
In spite of these critiques, the Kirsch conclusion was strong
since it seemed to rely on solid data while detractors were using
seemingly vague arguments. More recently, we performed a
re-analysis of the Kirsch et al. (2008) data (Fountoulakis and
Mo¨ller, 2010), reporting not only different results but also pro-
posing a different way of interpreting the data. Also the paper
‘Placebo, Prozac and PLos: significant lessons for psychophar-
macology’ has recently been published (Horder et al., 2010).
That paper commented on the methods used by Kirsch et al. in
their 2008 paper (Kirsch et al., 2008) and performed a limited
re-analysis of the data.
Although the paper by Horder et al. (2010) agrees in many
ways with us (namely, that the difference in the effectiveness of
active drug versus placebo is between 2.18 and 2.68 HRSD
points instead of 1.80), we sharply disagree on the interpreta-
tion of the situation. In their re-analysis, Horder and
colleagues suggest that themain problem in theKirsch analysis
was methodological; that is, Kirsch et al. used unusual or
unconventional methods to pool and analyse the data. They
also suggest a number of conceptual problems in the interpre-
tation (e.g. what ‘severity’ stands for, what the true placebo
effect stands for, etc.) In our opinion these are not the main
problems and they only turn our attention away from the core
of the issue.
There are two main problems with the Kirsch analysis.
The first concerns the method of analysis. We performed the
re-analysis by using simple averaging, weighting by sample size
and by the inverse variance. The differences in the results after
these different approaches were not that important, since the
correction of the effect size was minimal (Table 1).
Second, Kirsch et al. failed to report that (according to their
method) the change in HRSD score was slightly below the
threshold of 3 points suggested by the NICE for specific
antidepressants. According both to our analysis and to
Horder et al.’s analysis, the correct values are above 3 points
for venlafaxine and for paroxetine. This also points to a high
heterogeneity among antidepressants, making it problematic
to view the results of their meta-analysis as being equally rel-
evant to the whole class of antidepressants. Still, the respective
values for fluoxetine and nefazodone are low. It is to be noted
that it is impossible to calculate individual d-values without
calculating the change scores first, so these were interim results
in the process of the analysis and Kirsch et al. should have
reported them, especially in the frame of the importance of a
possible ‘clinical difference’ between drugs. Furthermore, four
RCTs concerned the elderly, leading to lower d-values since it
is known that the elderly constitute a refractory population
(Fountoulakis et al., 2003, 2004). A previous comment sug-
gested that at least the calculations were correct (e.g.
‘Undoubtedly the findings in this analysis are robust, as far
as the studies included in the analysis are concerned’) and that
all relevant results were published in the paper (McAllister-
Williams, 2008).
Theoretical interpretation of the data
However, the real problem lies in our understanding and
interpretation of the findings, and this constitutes a core
issue. Horder et al. (2010) write ‘. . .it makes no sense to say
that the increasing efficacy of antidepressants in more severe
depression is not due to an increase the response to medication
but is on the contrary due to decreasing response to placebo’.
This statement is very close to the arguments of Kirsch et al.
and may reflect the statement that ‘the pharmacological effects
are defined as [improvement with medication – improvement
with placebo]’ (Waring, 2008); however, it is essentially
misleading.
Theoretically, the Kirsch approach predicts that in the
chart of baseline HRSD (x-axis) versus effect size of interven-
tion (y-axis), which Kirsch et al. included as Figure 3 in their
paper (Kirsch et al., 2008), the placebo and the drug regression
lines should have been more or less parallel (which they
are not in any paper we know), thus reflecting that the effects
are additive (which we argue are not). There is no way that the
horizontal regression line of the drug can fit that approach and
interpretation. Both the classical psychopharmacological
approach in the design of RCTs and the Kirsch approach are
disputed by these non-parallel regression lines, simply
because they are not parallel. Indirectly, this assumption
implies a similar biochemical mechanism underlying both the
drug effect and the response in the placebo group, and also that
the placebo effect is always present and what is under question
is the drug effect (Figure 1).
However, if we step outside the usual assumptions, then
there is no dead-end and the explanation is simple: the
response in the placebo group and the drug effects are non-
additive, and antidepressants act independently of depression
severity, while the response in the placebo group is present
predominantly in milder cases. Clinically this makes sense;
Table 1. Analysis of the Kirsch data with different methods.
Active drug N¼ 3292 Placebo N¼ 1841
Baseline Change d-value SD Baseline Change d-value SD Diff. d
Difference
in change
Kirsch’s results – 9.60 1.24 – – 7.80 0.92 – 0.32 1.80
Simple averaging 25.63 10.46 1.27 8.32 25.45 7.53 0.92 8.37 0.35 2.93
Weighted by sample size 24.64 10.04 1.25 8.00 25.28 7.85 0.93 8.42 0.32 2.18
Weighted by inverse of the variance 24.64 10.16 1.28 8.00 25.28 7.48 0.93 8.42 0.35 2.68
Fountoulakis and Mo¨ller 745
 at LMU Muenchen on June 12, 2013jop.sagepub.comDownloaded from 
melancholic patients respond less to placebo while milder
depressive patients have an unstable clinical picture and spon-
taneous improvements which, in combination with the short
duration of the studies, inflates the response in the placebo
group. Of course there are other factors responsible for this
response – for example, natural course of the illness, natural
fluctuation, regression to the mean, and so on (Bland and
Altman, 1994a, 1994b) – but in a similar way almost all are
related tomilder forms of depression and technically constitute
unstable ‘noise’ and ‘artefacts’. On the contrary themedication
effect is reliable, valid and stable. A contrast of the composi-
tion of the drug and the response in the placebo group is shown
in Table 2. Some of the responses in the placebo group com-
ponents are fully present in the drug effect as well (e.g. the
regression to the mean); others are clearly almost absent (e.g.
expectancy). However, the rest might be partially present or
absent and this depends on specific circumstances. For exam-
ple, the natural fluctuation of the symptoms could be partially
present in the drug effect, but also it is possible that the drug
forces and levels out this fluctuation. The same could be true
for concomitant medication. An additional problem which
‘masks’ the true difference in the effect size is the problematic
properties of the HRSD; some of its items assess core features
of depression, others non-specific and transnosological symp-
toms that respond to a variety of agents (e.g. sleep, somatic
anxiety) and others might reflect side effects (e.g. loss of libido).
Kirsch et al. (2008) published a figure (Figure 3 in their
paper, reprinted as Figure 1 in Horder et al., 2010) showing
that the medication effect d-values do not increase with
increasing severity; however, Horder et al. in their Figure 2
suggested that the corresponding change in HRSD scores did
increase. We suggest in Figures 1 and 2 in our re-analysis paper
(Fountoulakis and Mo¨ller, 2010) that in this instance Kirsch
et al. were right. Adopting a raw difference in HRSD scores for
the y-axis leads to both regression lines having a positive slope;
however, this is largely an artefact, since even with random sets
of values for baseline and after-treatment scores, the difference
correlates approximately with baseline, with a coefficient of
0.7. Also this method does not take into account the variability
within studies. Thus, such a chart is not onlymistaken, but also
impossible to interpret. The use of effect size d-value has
observable advantages since it controls for the variability
within studies.
Since 2008, many commentators have suggested that anti-
depressants act only in severe depression; milder forms do
not respond, hence alternative treatment approaches are
more suitable for these patients. The industry strives to include
only the more severe patients in the RCTs in order to secure a
positive outcome. All of these are false approaches based on
widespread misconception and misinterpretation of the data.
An immediate consequence of this is that patients suffering
from mild depression are deprived from receiving antidepres-
sants, on the basis of this false interpretation of short-term
clinical trial data and the overvaluation of ‘alternative thera-
pies’. Long-term observations suggest depression is a chronic
relapsing disease.
The additivity thesis of pharmacological efficacy is central
in RCT logic, being the assumption that the specific or ‘true’
magnitude of the pharmacological effect is limited to the dif-
ference between the drug and placebo responses (Waring,
2008). This is a convenient and practical way to prove a specific
drug’s efficacy, and does not necessarily demand an identical
neurobiological mode of therapeutic action, although the
theory behind this method implies such a similarity. This is
because the method is ‘purely quantitative’ and thus demands
‘similar quality’. Kirsch’s scientific work is largely on ‘response
expectancy’ and has been the focus of Kirsch’s research for
decades, especially concerning hypnosis, psychotherapy, pla-
cebo effects, etc. In a further exploration of the early Gelfand
theory, response expectancy was found to be altered by previ-
ous experience, and even very small changes in the context of
presentation could affect individual differences in the placebo
response (entire placebo situation) (Gelfand et al., 1963), while
the response in the placebo group was found to significantly
associate with response expectancy (Whalley et al., 2008).
Essentially this model does not take into consideration the
fact that often placebo-arm patients receive additional treat-
ment, usually with benzodiazepines which strongly affect sev-
eral HRSD items. Patients treated with medication might
not experience the same impact of this add-on therapy even
if exposure were the same, because they already are receiving a
treatment which might influence these symptoms; the effect
Table 2. A possible model of the components of the drug effect and the
response in the placebo group. While the response in the placebo group
could be equal in size to 85% of the active drug effect, the underlying
mechanisms could be quite different. Figures are suggested based on
Kaptchuk et al. (2008) and others; see the text for details.
Drug effect Placebo effect % of effect
Regression to the mean yes yes 40%









Biochemical effect yes no 60%
Figure 1. Graphic representation of the active drug effect versus the
response in the placebo in group.
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might not be additive or a floor/ceiling effect could be present.
Even worse, similar exposure to add-on therapy might increase
the adverse events rate (e.g. sedation).
The Kirsch hypothesis concerning depression is that there
is a response which lies on a continuum from no intervention at
all (e.g. waiting lists) to neutral placebo, then to active and
augmented placebo including psychotherapy, and finally
to antidepressants which exert a slightly higher efficacy, prob-
ably because blinding is imperfect due to side effects (enhanced
placebo) (Kirsch, 2004, 2005, 2008a, 2008b, 2009a; Kirsch and
Johnson, 2008; Kirsch and Moncrieff, 2007). In order to con-
firm this theory, namely that all interventions including anti-
depressants work through ‘response expectancy’, one needs to
prove that interventions with similar presentation characteris-
tics have similar efficacy and that differences in efficacy can
be explained by differences in the magnitude of ‘response
expectancy’.
Research so far suggests that there may not be one placebo
response but several, and there are multiple mechanisms
involved, which may differ as a function of the context in
which the placebo is presented. Co-medication, usually with
benzodiazepines according to clinical needs, is also responsible
for a portion of the response in the placebo group. In this
line of research, there was some data suggesting that a large
component of the ‘active’ treatment was placebo-mediated
(Moncrieff andKirsch, 2005). Themeta-analysis of antidepres-
sant trials comparing those with a run-in period to those
without one suggests that this method does not increase
drug–placebo differences (Posternak et al., 2002; Trivedi and
Rush, 1994), which means that maybe any patient could be a
placebo-responder and this is not possible to predict. There are
data suggesting that the proportion of patients who respond
are indeed on a continuum (e.g. 28% on waiting list, 44% in
limited group, and 62% in augmented group; Kaptchuk et al.,
2008). The model, however, predicts that all augmented place-
bos should have similar efficacy and thus this theory does not
explain why psychotherapy is inferior to pharmacotherapy
(Cuijpers et al., 2010a, 2010b) since both are considered to
have similar ‘enhanced placebo’ qualities according to this
line of thinking. Kirsch seems to consider psychotherapy
closer to active placebo and antidepressants closer to aug-
mented placebo, partially because of methodological issues
concerning the ability to blind (side effects make patients real-
ize that they are taking drug instead of placebo, and this
increases their expectation) (Kirsch, 2009a).
The final finding in support of the Kirsch theory was the
results of his 2008 meta-analysis (Kirsch et al., 2008), which
reported that the effect size and the magnitude of change in
HDRS score were small (effect size d-value below 0.50 and
change in HRSD equal to 1.80 points) and thus antidepres-
sants fell well below criteria for clinical relevance suggested by
the NICE; however, these criteria are not generally accepted
(Mo¨ller, 2008). Similar findings were reported by Barbui et al.
for paroxetine alone (Barbui et al., 2008). Kirsch et al. also
reported that efficacy reaches clinical relevance only in trials
involving the most extremely depressed patients, and that this
pattern is due to a decrease in the response in the placebo group
rather than an increase in the response to medication. They
also found no linear relation between severity and response to
medication. However, the reported ‘efficacy’ based on RCTs
using a ‘last observation carried forward’ (LOCF) analysis is,
in fact, a hybrid of both efficacy and tolerability.
As a final requirement for the model to be considered as
correct, one needs to prove that antidepressants are not
significantly better than placebo and that there are no differ-
ences among antidepressants. The supposed equal efficacy of
all types of antidepressants supports this thesis – that is, SSRIs,
tricyclics and monoamine oxidase inhibitors, despite the fact
that they have different modes of operation; the supposed sim-
ilar efficacy of some active drugs that are not considered anti-
depressants (amylobarbitone, lithium, liothyronine and
adinazolam); and the high correlation between the placebo
and the drug response (Kirsch, 2000), which implies a similar
mechanism underlying response no matter the treatment
Figure 2. Graphic representation of the active drug effect versus the response in the placebo in group according to two different models, the additivity
model and the alternative model. A: expectancy effect; B: regression to the mean, natural course of illness, fluctuation of symptoms; C: biochemical effect
of the active drug.
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intervention. However, this argument is not strong, since in
general medicine different classes of medication acting through
different pathwaysmight treat the samemedical condition. It is
to be noted that there are neuroimaging data suggesting that
brain alterations in patients who improve are independent of
treatment intervention (Konarski et al., 2009; Martin et al.,
2001), while others suggest that the neurochemistry behind
the drug response and the response in the placebo group are
different (Mayberg et al., 2002).
However, the finding that antidepressants act at the same
magnitude irrespective of initial severity while the response in
the placebo group depends on it suggests a different mecha-
nism underlying these two different interventions, with antide-
pressants being unrelated to response expectancy. Response
expectancy is strongly related to severity of depression
(according to cognitive theory), thus the regression lines in
Kirsch et al.’s Figures 2 and 3 should have been parallel.
This is the reason why, at higher severity, the response in the
placebo group drops close to the levels of waiting list. These
authors stress the finding that there was a negative relation
between severity and the response in the placebo group,
whereas there was no difference between those with relatively
low and relatively high initial depression in their response
to drug. Thus, the increased benefit for extremely depressed
patients seems attributable to a decrease in responsiveness in
the placebo group, rather than an increase in responsiveness to
medication. However, they do not explain how this fits their
position. Our analysis revealed that over the years, there was
an increase in both the active drug and the placebo groups with
regression lines being parallel (Figure 2 of the re-analysis paper
of Fountoulakis and Mo¨ller, 2010), maybe suggesting that the
techniques developed over the years to support and keep
patients in the study also increase expectancy.
Other data against the Kirsch theory come from a recent
meta-analysis suggesting escitalopram is the most effective
agent with also the highest tolerability (Cipriani et al., 2009).
This means that increased efficacy cannot be explained on the
basis of unblinding because of side effects: escitalopram is
better tolerated than several other antidepressants.
If we reject the additivity hypothesis and accept that there is
a radically different composition between the drug and the
response in the placebo group, then a different picture emerges.
If we accept that the proportion of patients who respond are
indeed on a continuum with around 28% on waiting list, 44%
in the limited group, and 62% in the augmented group
(Kaptchuk et al., 2008), and we apply these data in the list of
Table 2 (rounded, suggesting an overall 75% response to
active drug and the placebo effect to be 85% of the drug
effect), we arrive at a rough model of qualitative and quanti-
tative differences between the drug and the placebo response.
According to such a model (Figure 2), although the placebo
effect could be equal in size to 85%of the active drug effect, the
qualitative composition is quite different and this difference is
responsible for the long-term beneficial effect of pharmaco-
therapy. It is interesting that Kirsch seems to agree with this
approach and has suggested that ‘If there is a reasonably large
pharmacologic effect, then it cannot be an addition to the
placebo effect, in which case conventional double-blind studies
are not appropriate for testing the drug effects’ (Kirsch, 2000).
We completely agree with this position. Either medications are
similar to placebo – and there is a combined effect maybe only
in the most severe cases of depression – or medications are
superior to placebo: they act independently of initial severity
and the additivity thesis is irrelevant. In essence we agree with
the line of reasoning ofKirsch on this issue, but we arrive at the
opposite conclusion.
Conclusion
A summary of conclusions is shown in Table 3. We argue that
the Kirsch results themselves suggest that although a large
percentage of the response in the placebo group is due to expec-
tancy, this is not true for the active drug, and that the drug and
placebo effects are not additive. The drug effect is unrelated to
depression severity while the placebo response is reduced in
more severe depression. If this is confirmed in future research,
then the value of the RCT as the major tool for investigating
the efficacy of antidepressants may be doubtful.
Unfortunately, the authors are currently in no position to pro-
pose an alternative.
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